Advanced Filters
noise

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials

A listing of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 103 clinical trials
E Edison Leung, MD

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

The purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).

22 - 85 years of age Both Phase N/A
T Thomas DESMIDT

Nitrous Oxide for Late-Life Depression - PROTO-BRAIN

Resistant Depression is a common condition in older adults and there is an urgent need for novel antidepressant in this population. Nitrous Oxide (N2O) has recently shown rapid antidepressant effect in midlife depression but no study has currently investigated the efficacy and safety of N2O in Late-Life Depression (LLD), while …

60 - 90 years of age Both Phase N/A
S Sonia Prashar

BPL-003 Efficacy and Safety in Treatment Resistant Depression

This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).

18 - 75 years of age Both Phase 2

A Trial of GH001 in Patients With Treatment-resistant Depression

The aim of this randomized, double-blind, placebo-controlled, phase 2b clinical trial is to investigate the safety and efficacy of GH001 (containing mebufotenin [5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT]) in patients with treatment-resistant depression (TRD). The study is comprised of a 7-day double-blind (DB) part (Part 1) and a 6-month open-label extension (OLE) part (Part …

18 - 64 years of age Both Phase 2
E Esther Parra Vidales

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

18 - 100 years of age Both Phase 3
C Carmen Torres

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.

18 - 100 years of age Both Phase N/A

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: Does psilocybin with assisted therapy help improve symptoms for people with depression? How long do the effects of this treatment last? Participants …

18 - 70 years of age Both Phase 3
S Sebastian Swane

Schema Therapy for Patients With Chronic Treatment Resistant Depression

The goal of this clinical study is to test a particular form of psychotherapy, called schema therapy, for people with difficult-to-treat depression (when depression is very lengthy or difficult to cure with antidepressive medication). Researchers will compare the group of participants receiving schema therapy to a group receiving standard psychotherapeutic …

18 - 65 years of age Both Phase N/A

Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression

This study is a multicenter, randomized, double-blind, and sham-controlled trial using the identical protocol as the SNT to replicate the antidepressant efficacy of SNT for TRD. Patients will be recruited and randomly assigned (1:1 ratio) to receive active or sham groups from 5 hospitals in China. The interventions will last …

22 - 65 years of age Both Phase N/A

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression

We aim to evaluate the safety and efficacy of pBFS-guided high-dose rTMS therapy with short inter-session interval for patients with treatment-resistant depression

18 - 65 years of age Both Phase N/A

Rewrite in simple language using AI